Monoclonal antibody ADCC cHAb18 - Pacific Meinuoke Biopharmaceutical

Drug Profile

Monoclonal antibody ADCC cHAb18 - Pacific Meinuoke Biopharmaceutical

Alternative Names: HAb18G/CD147-targeting monoclonal antibody

Latest Information Update: 30 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pacific Meinuoke Biopharmaceutical
  • Developer Fourth Military Medical University; Pacific Meinuoke Biopharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Membrane glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Lung cancer

Most Recent Events

  • 27 Nov 2015 Clinical trials in Lung cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top